The company said an experimental drug to improve the delivery of anti-cancer medications to solid tumors has shown promise in ...

tolerability, advantages, and safety profile of NK cell therapies, including NKX019 for the treatment of autoimmune diseases, such as LN, and NHL; plans and timelines for the future availability and ...

Q1 2024 Earnings Call Transcript May 8, 2024 Revolution Medicines, Inc. isn’t one of the 30 most popular stocks among hedge ...

In preparation for later stage clinical trials, the company is conducting a formulation bridging and titration study to evaluate capsule versus tablet pharmacokinetics (PK) and explore different ...

Markets were more subdued in April after the strong start to the year. The S&P/ASX 200 Accumulation Index was down 2.9% and ...

Q1 2024 Earnings Call Transcript May 8, 2024 CytomX Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.1669, ...

These multicenter, randomized, double-blind, placebo-controlled trials are evaluating the clinical efficacy, safety, and tolerability of 15 mg or 25 mg of azetukalner administered with food as ...

Dynavax Technologies Corporation misses on earnings expectations. Reported EPS is $-0.06698 EPS, expectations were $-0.05.

Merck (MRK) stock slipped as a Phase 3 trial for Keytruda with chemotherapy as a first-line option fails in endometrial ...

Drs Jacob Sands and Benjamin P. Levy discuss antibody-drug conjugates in lung cancer treatment, including differences in ...

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors ...

An autologous and personalized regulatory T cell therapy is safe in patients with type 1 diabetes, but does not help preserve ...